BioCentury's websites will be down for upgrades starting at 9 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

5:12 PM
 | 
Sep 28, 2007
 |  BC Extra  |  Top Story

Idenix restructures

IDIX will restructure and reduce headcount by about 100 (33%) to 200 to focus on its HCV and HIV programs. IDIX also said it amended its deal with Novartis (NVS; SWX:NOVN) for HBV drug Tyzeka telbivudine (Sebivo-EU) and discontinued development of valtorcitabine, an oral nucleoside analog that was in Phase IIb testing as a fixed-dose combination with...

Read the full 274 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$50 USD
More Info >